Want to see PODD full AI Analyst Report?
PODD Stock Chart & Stats
$163.26
$4.88(3.08%)
At close: 4:00 PM EDT
$163.26
$4.88(3.08%)
Day’s Range― - ―
52-Week Range$138.79 - $354.88
Previous CloseN/A
Volume1.15M
Average Volume (3M)1.40M
Market Cap
$11.45B
Enterprise Value$15.20K
Total Cash (Recent Filing)$480.40M
Total Debt (Recent Filing)$948.10M
Price to Earnings (P/E)38.4
Beta0.46
Next Earnings
Aug 05, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.31
Shares Outstanding69,264,670
10 Day Avg. Volume1,424,938
30 Day Avg. Volume1,404,203
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$222.95Price Target Upside36.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)6.48
Revenue Forecast (FY)$3.32B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelA consumables-driven model (disposable pods replaced regularly) creates predictable, repeat revenue and high lifetime customer value. This structural cash flow cadence supports durable sales visibility, recurring gross-margin contribution and easier planning for manufacturing and distribution investments.
Multi-year Revenue Scale And High Gross MarginsSustained rapid revenue growth alongside industry-leading gross margins signals structural competitiveness in product design and manufacturing. High margins provide operating leverage as scale grows, enabling reinvestment in R&D, commercial expansion and margin-resilient profitability over the medium term.
Strengthened Cash Generation And Balance SheetA turnaround from negative to multi-hundred-million FCF materially improves financial flexibility. Consistent free cash enables capex for capacity, selective buybacks and debt reduction, reducing leverage risk and giving management choices to support durable growth and withstand execution hiccups.
Bears Say
Product Safety CorrectionsLarge-scale corrections and reported serious adverse events impose direct remediation costs and elevate regulatory and reputational risk. Persistent or recurring manufacturing quality issues can erode provider/payer trust, complicate reimbursement, slow new customer adoption and increase ongoing compliance and quality-control expenses.
Retention Pressure From Type 2 MixA growing Type 2 customer segment can exhibit higher early attrition versus Type 1 users, reducing pods-per-patient lifetime. Structural declines in retention lower recurring revenue and weaken unit economics, requiring sustained investment in onboarding, education and care programs to preserve long-term refill volumes.
Capex Ramp Limits Near-term Free Cash Flow ExpansionPlanned manufacturing and automation investments are necessary for scale but compress near-term cash conversion. Flat FCF despite rapid revenue growth reduces optionality for accelerated deleveraging or additional shareholder returns, and raises execution risk if capacity investments lag demand or cost more than anticipated.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $138.79 and its highest was $354.88 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $11.45B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on May 06, 2026. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.199 by $0.221.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.45.
How many shares outstanding does Insulet have?
Insulet has 69,264,670 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.42 in its last earnings report, beating expectations of $1.199. Following the earnings report the stock price went down -9.7%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$222.95 (36.56% Upside)
$222.95 (36.56% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 84.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $838.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.07%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust revenue growth (30% constant-currency company; 45% international), margin expansion, ~40% EPS growth, raised full-year guidance, product R&D progress (Libre 3 Plus integration, Omnipod 6, fully closed-loop type 2) and healthy cash generation and buybacks. Offsetting items were largely identifiable, management-described headwinds and investments — including a voluntary medical device correction with related costs (~$12M), excess & obsolescence charges during a product transition (impacting gross margin >150 bps), short-term seasonality affecting Q1 U.S. new customer starts, modest retention pressure as type 2 mix grows, and elevated interest/cost pressures. Overall, positives (strong growth, margin expansion, product pipeline, guidance raise and cash actions) materially outweigh the disclosed challenges, which management framed as manageable, partly one-time, or investments to support durable growth.View all PODD earnings summariesPODD Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
PODD Stock 12 Month Forecast
Average Price Target
$222.95
▲(36.56% Upside)
Technical Analysis
Ownership Overview
0.33% Insiders
33.28% Mutual Funds
3.58% Other Institutional Investors
33.55% Public Companies and Individual Investors